Serologic Response of 2 Versus 3 Doses and Intradermal Versus Intramuscular Administration of a Licensed Rabies Vaccine for Preexposure Prophylaxis.
Adolescent
Adult
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ immunology
Female
Humans
Immunization Schedule
Immunization, Secondary
Immunogenicity, Vaccine
Injections, Intradermal
Injections, Intramuscular
Linear Models
Male
Middle Aged
Post-Exposure Prophylaxis
Pre-Exposure Prophylaxis
/ methods
Rabies
/ prevention & control
Rabies Vaccines
/ administration & dosage
Rabies virus
/ immunology
Vaccination
Young Adult
immunogenicity
intradermal
intramuscular
rabies
vaccine
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
07 04 2020
07 04 2020
Historique:
received:
18
10
2019
accepted:
04
12
2019
pubmed:
6
12
2019
medline:
5
2
2021
entrez:
6
12
2019
Statut:
ppublish
Résumé
The World Health Organization recommends intradermal (ID) administration of rabies vaccine for preexposure prophylaxis. In a randomized trial in adults assigned to 1 of 6 treatment groups (ID vs intramuscular [IM], 2 vs 3 doses, and controls), rabies neutralizing antibody titers were measured to 1 year postvaccination. ID vaccination produced acceptable antibody levels in all subjects (2- and 3-dose groups). At day 365, acceptable levels were 40% for IM and 50% for ID 2-dose schedule, and 70% for IM and 60% for ID 3-dose schedule. ID rabies vaccination induces acceptable antibody titers at a fraction of the dose. NCT02374814.
Sections du résumé
BACKGROUND
The World Health Organization recommends intradermal (ID) administration of rabies vaccine for preexposure prophylaxis.
METHODS
In a randomized trial in adults assigned to 1 of 6 treatment groups (ID vs intramuscular [IM], 2 vs 3 doses, and controls), rabies neutralizing antibody titers were measured to 1 year postvaccination.
RESULTS
ID vaccination produced acceptable antibody levels in all subjects (2- and 3-dose groups). At day 365, acceptable levels were 40% for IM and 50% for ID 2-dose schedule, and 70% for IM and 60% for ID 3-dose schedule.
CONCLUSIONS
ID rabies vaccination induces acceptable antibody titers at a fraction of the dose.
CLINICAL TRIALS REGISTRATION
NCT02374814.
Identifiants
pubmed: 31802120
pii: 5658469
doi: 10.1093/infdis/jiz645
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Rabies Vaccines
0
Banques de données
ClinicalTrials.gov
['NCT02374814']
Types de publication
Clinical Trial, Phase IV
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1494-1498Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.